Illumina (NASDAQ:ILMN) PT Lowered to $242.00 at Royal Bank of Canada

Illumina (NASDAQ:ILMN) had its target price trimmed by Royal Bank of Canada from $249.00 to $242.00 in a report published on Monday, Benzinga reports. The brokerage currently has an outperform rating on the life sciences company’s stock.

Several other equities analysts have also recently issued reports on the company. Barclays raised their price objective on Illumina from $85.00 to $100.00 and gave the stock an underweight rating in a research note on Wednesday, April 10th. StockNews.com started coverage on shares of Illumina in a report on Sunday. They issued a buy rating for the company. Stephens reiterated an overweight rating and set a $170.00 price objective on shares of Illumina in a research note on Tuesday, May 7th. Evercore ISI decreased their target price on Illumina from $195.00 to $175.00 and set an outperform rating for the company in a research note on Tuesday, June 11th. Finally, OTR Global reaffirmed a mixed rating on shares of Illumina in a report on Wednesday, March 20th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $157.62.

Illumina Price Performance

ILMN opened at $105.28 on Monday. The company has a market capitalization of $16.77 billion, a P/E ratio of -12.92 and a beta of 1.15. The company has a 50-day moving average of $110.95 and a 200-day moving average of $126.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 1-year low of $89.00 and a 1-year high of $195.64.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company earned $0.08 earnings per share. Illumina’s quarterly revenue was down 1.0% on a year-over-year basis. Equities analysts expect that Illumina will post 0.98 EPS for the current fiscal year.

Institutional Trading of Illumina

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Illumina by 0.4% during the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares in the last quarter. Edgewood Management LLC increased its position in shares of Illumina by 4.6% during the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock valued at $957,762,000 after purchasing an additional 302,222 shares during the period. Baillie Gifford & Co. raised its stake in shares of Illumina by 8.7% in the 1st quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock worth $787,725,000 after buying an additional 460,649 shares in the last quarter. WCM Investment Management LLC lifted its holdings in shares of Illumina by 2,232.3% in the first quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock valued at $463,760,000 after buying an additional 3,232,418 shares during the period. Finally, Capital World Investors lifted its holdings in shares of Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after buying an additional 801,814 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.